Company registration number 09526893 (England and Wales)
ISLINGTON PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
ISLINGTON PHARMA LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
ISLINGTON PHARMA LIMITED
BALANCE SHEET
AS AT 30 APRIL 2025
30 April 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
4,361
5,318
Current assets
Stocks
49,575
49,075
Debtors
4
280,391
545,638
Cash at bank and in hand
498,569
90,203
828,535
684,916
Creditors: amounts falling due within one year
5
(303,430)
(276,390)
Net current assets
525,105
408,526
Net assets
529,466
413,844
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
529,366
413,744
Total equity
529,466
413,844

For the financial year ended 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 22 January 2026
Aurangzeb Yousaf
Director
Company registration number 09526893 (England and Wales)
ISLINGTON PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
- 2 -
1
Accounting policies
Company information

Islington Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit A 31 North Road, Islington, London, UK, N7 9GL.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
18% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

1.7
Pensions

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

ISLINGTON PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
- 3 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
6
6
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 May 2024 and 30 April 2025
18,802
Depreciation and impairment
At 1 May 2024
13,484
Depreciation charged in the year
957
At 30 April 2025
14,441
Carrying amount
At 30 April 2025
4,361
At 30 April 2024
5,318
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
248,557
219,103
Other debtors
31,834
326,535
280,391
545,638
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
108,951
121,405
Corporation tax
40,560
28,645
Other taxation and social security
3,978
2,110
Other creditors
149,941
124,230
303,430
276,390
ISLINGTON PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
- 4 -
6
Ultimate Controlling Party

The controlling party is Aurangzeb Yousaf.

2025-04-30 2024-05-01 false false false 22 January 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Aurangzeb Yousaf 09526893 2024-05-01 2025-04-30 09526893 2025-04-30 09526893 2024-04-30 09526893 core:OtherPropertyPlantEquipment 2025-04-30 09526893 core:OtherPropertyPlantEquipment 2024-04-30 09526893 core:CurrentFinancialInstruments core:WithinOneYear 2025-04-30 09526893 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 09526893 core:WithinOneYear 2025-04-30 09526893 core:WithinOneYear 2024-04-30 09526893 core:CurrentFinancialInstruments 2025-04-30 09526893 core:CurrentFinancialInstruments 2024-04-30 09526893 core:ShareCapital 2025-04-30 09526893 core:ShareCapital 2024-04-30 09526893 core:RetainedEarningsAccumulatedLosses 2025-04-30 09526893 core:RetainedEarningsAccumulatedLosses 2024-04-30 09526893 bus:Director1 2024-05-01 2025-04-30 09526893 core:PlantMachinery 2024-05-01 2025-04-30 09526893 2023-05-01 2024-04-30 09526893 core:OtherPropertyPlantEquipment 2024-04-30 09526893 core:OtherPropertyPlantEquipment 2024-05-01 2025-04-30 09526893 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 09526893 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-04-30 09526893 bus:FRS102 2024-05-01 2025-04-30 09526893 bus:AuditExemptWithAccountantsReport 2024-05-01 2025-04-30 09526893 bus:FullAccounts 2024-05-01 2025-04-30 xbrli:pure xbrli:shares iso4217:GBP